Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16352-16365

  Jiang, Hong Lin ^a,b   Sun, He Fen ^a,b   Gao, Shui Ping ^a,b   Li, Liang Dong ^a,b   Hu, Xin ^a   Wu, Jiong ^a,b   Jin, Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Metastatic breast cancer; RAB1B; TGF SMAD signaling; Triple negative

Indexed keywords

BIOLOGICAL MARKER; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBIQUITIN; RAB PROTEIN; RAB1B PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE RAS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAB1B GENE; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL MOTION; ENZYME ACTIVATION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; SECONDARY; TISSUE MICROARRAY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROGNOSIS; RAB1 GTP-BINDING PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TRIPLE NEGATIVE BREAST NEOPLASMS; UBIQUITIN;

EID: 84937706053     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3877     Document Type: Article

References (31)

1. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24:5652-5657.
2. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P and Tan PH. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010; 23:123-133.
3. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS and Tan PH. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol. 2010; 34:956-964.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13:4429-4434.
5. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109:1721-1728.
6. Tischkowitz M1, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO and WD. F. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7:134-144.
7. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ. Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16:2659-2671.
8. Wiggans RG, Woolley PV, Smythe T, Hoth D, Macdonald JS, Green L and Schein PS. Phase-II trial of tamoxifen in advanced breat cancer. Cancer Chemother Pharmacol. 1979; 3:45-48.
9. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13:2329-2334.
10. Lin HC, Zhang FL, Geng Q, Yu T, Cui YQ, Liu XH, Li J, Yan MX, Liu L, He XH, Li JJ and Yao M. Quantitative proteomic analysis identifies CPNE3 as a novel metastasispromoting gene in NSCLC. J Proteome Res. 2013; 12:3423-3433.
11. Cheng KW, Lahad JP, Gray JW and Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 2005; 65:2516-2519.
12. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C and Green JE. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2002; 62:5325-5335.
13. Nikoshkov A, Broliden K, Attarha S, Sviatoha V, Hellstrom AC, Mints M and Andersson S. Expression pattern of the PRDX2, RAB1A, RAB1B, RAB5A and RAB25 genes in normal and cancer cervical tissues. Int J Oncol. 2015; 46:107-112.
14. Kalluri R and Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest. 2009; 119:1420-1428.
15. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massague J. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436:518-524.
16. Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M and Wang XJ. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest. 2005; 115:1714-1723.
17. Korpal M, Yan J, Lu X, Xu S, Lerit DA and Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009; 15:960-966.
18. Hu Z, Zhang Z, Guise T and Seth P. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-beta receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther. 2010; 21:1623-1629.
19. Seoane J. The TGFBeta pathway as a therapeutic target in cancer. Clin Transl Oncol. 2008; 10:14-19.
20. Wilson BS, Nuoffer C, Meinkoth JL, McCaffery M, Feramisco JR, Balch WE and Farquhar MG. A Rab1 mutant affecting guanine nucleotide exchange promotes disassembly of the Golgi apparatus. J Cell Biol. 1994; 125:557-571.
21. Piper RC, Dikic I and Lukacs GL. Ubiquitin-dependent sorting in endocytosis. Cold Spring Harb Perspect Biol. 2014; 6.
22. Mellman I and Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013; 5:a016949.
23. Tsai CH, Cheng HC, Wang YS, Lin P, Jen J, Kuo IY, Chang YH, Liao PC, Chen RH, Yuan WC, Hsu HS, Yang MH, Hsu MT, et al. Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis. Nat Commun. 2014; 5:4804.
24. Wang C, Yoo Y, Fan H, Kim E, Guan KL and Guan JL. Regulation of Integrin beta 1 recycling to lipid rafts by Rab1a to promote cell migration. J Biol Chem. 2010; 285:29398-29405.
25. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA and Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3:537-549.
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
27. He H, Dai F, Yu L, She X, Zhao Y, Jiang J, Chen X and Zhao S. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr. 2002; 10:231-242.
28. Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y, Marsh JW, Michalopoulos GK and Luo JH. Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation. Am J Pathol. 2012; 180:1495-1508.
29. Zhai H, Song B, Xu X, Zhu W and Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene. 2013; 32:1570-9.
30. Ikushima H and Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010; 10:415-424.
31. Nagaraj NS and Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010; 19:77-91.